It's a flop: Gilead­'s top late-stage drug selon­sert­ib flunked its first Phase III NASH tri­al

Gilead’s high pro­file STEL­LAR-4 study of its top late-stage NASH drug selon­sert­ib has hit the fin­ish line, and it’s start­ing out Phase III re­sults with a big-time fail­ure.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.